Oruka Therapeutics GC sells 1,039 shares

Oruka Therapeutics’ General Counsel reported an automatic sell-to-cover tax sale tied to RSU vesting, with 29,995 shares remaining directly held.

Rhea-AI Filing Summary

Oruka Therapeutics, Inc. (ORKA) reported that General Counsel Paul T. Quinlan sold 1,039 shares of common stock on September 15, 2026 at $95.71 per share. According to the company, this automatic, non-discretionary sale was a sell-to-cover transaction to satisfy tax withholding obligations from vesting restricted stock units, leaving him with 29,995 directly held shares.

Insider Trade Summary

Net Seller: 1,039 shares

Net Sell 1 txn

Insider Quinlan Paul T

Role General Counsel

Sold 1,039 shs ($99K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	1,039	$95.71	$99K

Holdings After Transaction: Common Stock — 29,995 shares (Direct)

Footnotes (1)

1. F1. The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.

Key Figures

Shares sold: 1,039 shares Sale price per share: $95.71 per share Shares held after transaction: 29,995 shares

3 metrics

Shares sold 1,039 shares Common stock sold on September 15, 2026 in sell-to-cover transaction

Sale price per share $95.71 per share Price for the 1,039 shares sold on September 15, 2026

Shares held after transaction 29,995 shares Directly held Oruka Therapeutics common shares following the sale

Key Terms

sell-to-cover procedure, tax withholding obligations, restricted stock units

3 terms

sell-to-cover procedure financial

"automatic, non-discretionary, sell-to-cover procedure to satisfy tax"

tax withholding obligations financial

"procedure to satisfy tax withholding obligations arising in connection"

restricted stock units financial

"obligations arising in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ORKA report for its General Counsel?

Oruka Therapeutics reported that General Counsel Paul T. Quinlan sold 1,039 shares of common stock on September 15, 2026 at $95.71 per share in an automatic sell-to-cover transaction for tax withholding on vested RSUs.

How many ORKA shares does the General Counsel hold after the reported sale?

After the sell-to-cover transaction, General Counsel Paul T. Quinlan directly holds 29,995 shares of Oruka Therapeutics common stock, as reported in the filing.

Was the ORKA insider sale a discretionary open-market trade?

No. The filing states the sale was effected under Oruka Therapeutics’ automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising from the vesting of restricted stock units.

What was the price per share in the ORKA insider’s sell-to-cover transaction?

The reported sale by Oruka Therapeutics’ General Counsel occurred at a price of $95.71 per share for the 1,039 shares sold.

Is the ORKA Form 4 transaction reported under a Rule 10b5-1 trading plan?

The document’s Rule 10b5-1 checkbox is not affirmed, but the footnote explains the sale followed Oruka Therapeutics’ automatic, non-discretionary, sell-to-cover procedure for RSU-related tax withholding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 07:14 PM Accepted by SEC EDGAR 09/15/2026 - 07:14 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Quinlan Paul T

(Last) (First) (Middle)

C/O ORUKA THERAPEUTICS, INC.

855 OAK GROVE AVE., SUITE 100

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oruka Therapeutics, Inc. [ ORKA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2026		S(1)		1,039	D	$95.71	29,995	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.

	/s/ Paul Quinlan	09/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)